CDC Says Prioritize Use of Antibiotic for Syphilis After Shortage Announced

All products are currently on backorder, which is expected to resolve by July 2016
All products are currently on backorder, which is expected to resolve by July 2016

The Food and Drug Administration (FDA) reported a shortage of Bicillin L-A (penicillin G benzathine suspension; Pfizer) Injection due to manufacturing delays.

The shortage affects the following formulations:

  • Bicillin L-A 600,000U Pediatric Injection
  • Bicillin L-A 1,200,000U/2mL 
  • Bicillin L-A 2,400,000U/4mL 

All products are currently on backorder, which is expected to resolve by July 2016. The products are on allocation and inventory should be verified with wholesalers and distributors. 

Bicillin L-A is a penicillinase-sensitive penicillin indicated for susceptible infections, including mild to moderate upper respiratory strep infections and syphilis. Benzathine penicillin G is the recommended treatment for syphilis and is the only option for pregnant women infected with or exposed to syphilis. It is also indicated as follow-up prophylaxis of rheumatic heart disease and acute glomerulonephritis. 

The Centers for Disease Control and Prevention (CDC) recommend that until the normal stock of Bicillin L-A is available, clinicians should consider prioritizing Bicillin L-A for the treatment of syphilis especially in pregnant women infected with or exposed to syphilis. 

For more information call (800) 533-4535 or visit FDA.gov.

Loading links....